Last reviewed · How we verify
Placebo for ferrous fumarate
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
Placebo for ferrous fumarate, marketed by Maastricht University Medical Center, holds a niche position in the iron supplement market. The key composition patent is set to expire in 2028, providing a period of exclusivity and potential revenue protection. The primary risk lies in the lack of clear competitive advantages and key trial results, which may limit market adoption and growth.
At a glance
| Generic name | Placebo for ferrous fumarate |
|---|---|
| Also known as | Placebo tablets |
| Sponsor | Maastricht University Medical Center |
| Modality | Small molecule |
| Therapeutic area | Research/Clinical Trial Control |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to measure the effect of an active drug against baseline or psychological expectation. In this case, it serves as a comparator to ferrous fumarate (an iron supplement) in a research study. Any observed effects are attributable to the placebo effect or natural disease course rather than active drug mechanism.
Approved indications
- Control arm in ferrous fumarate clinical trial
Common side effects
Key clinical trials
- The Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive Age (NA)
- The Efficacy of Minayo Iron-rich Nutritional Gummies on Female Anemia, Skin Condition and Qi-blood Deficiency Syndrome (NA)
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448) (PHASE3)
- The Use of Iron Therapy for Patients With Anemia After Caesarean Section (PHASE4)
- Safe and Efficacious Iron for Children in Kenya (PHASE2, PHASE3)
- Effects of Iron and/or Zinc Supplementation in Mexican School Children Exposed to Lead (NA)
- A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo (PHASE2)
- Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for ferrous fumarate CI brief — competitive landscape report
- Placebo for ferrous fumarate updates RSS · CI watch RSS
- Maastricht University Medical Center portfolio CI